L’Oréal has entered into a research and development partnership with epigenomics testing specialist TruDiagnostic to better understand the links between epigenomic markers and "beauty indicators" to advance longevity-focused innovation "from within."
Epigenomics explores heritable changes that occur without altering the DNA sequence itself. Epigenetics encompasses processes that modify gene activity without changing the underlying DNA, resulting in inheritable transformations.
The L'Oreal-TruDiagnostic partnership will feature "studies designed to unlock the intricate relationship between epigenetics and beauty" to develop innovations that boost long-term skin and hair health by triggering "the hallmarks of longevity activation."
This innovation could theoretically enhance aesthetic benefits and overall well-being, L'Oreal argues.
“Partnering with TruDiagnostic represents a significant milestone for us,” says Guive Balooch, head of open innovation and augmented beauty at L’Oréal. “By combining our deep understanding of beauty biology with TruDiagnostic’s cutting-edge expertise in epigenomics, we are poised to lead the field of longevity biomarker discoveries that will bring new product offerings and valuable diagnostic insight to our consumers, to proactively care for their skin and hair health with the best longevity science solutions”.
Matthew Dawson, CEO of TruDiagnostic, adds, “We are excited to collaborate with L’Oréal to explore the links between epigenetic markers and beauty. Epigenomics has the potential to revolutionize how we understand beauty at a biological level. Together, we aim to lead the charge in integrating epigenetic science into the beauty industry, creating innovative products that truly reflect the future of beauty and longevity.”
